# Codexis, Inc.: overview CDXS · Nasdaq · CIK 1200375 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cdxs.md) · [Financials](/companies/cdxs/financials.md) · [Filings](/companies/cdxs/filings.md) · [Insiders](/companies/cdxs/insiders.md) Latest reported revenue: [$14.9m](/filings/0001200375-26-000019.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001200375-26-000019). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.8](/filings/0001200375-25-000016.md) | [21.5 d](/filings/0001200375-26-000006.md) | [7.5](/filings/0001200375-26-000012.md) | [15.3](/filings/0001200375-26-000019.md) | [8.6](/filings/0001200375-25-000016.md) | [38.9 d](/filings/0001200375-26-000006.md) | [15.2](/filings/0001200375-26-000012.md) | [14.9](/filings/0001200375-26-000019.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(129.0%)](/filings/0001200375-25-000016.md) | [(34.2%) d](/filings/0001200375-26-000006.md) | [(271.6%)](/filings/0001200375-26-000012.md) | [(83.9%)](/filings/0001200375-26-000019.md) | [(220.3%)](/filings/0001200375-25-000016.md) | [27.1% d](/filings/0001200375-26-000006.md) | [(52.7%)](/filings/0001200375-26-000012.md) | [(75.3%)](/filings/0001200375-26-000019.md) | | Net margin | % | [(160.8%)](/filings/0001200375-25-000016.md) | [(48.4%) d](/filings/0001200375-26-000006.md) | [(274.3%)](/filings/0001200375-26-000012.md) | [(86.6%)](/filings/0001200375-26-000019.md) | [(228.1%)](/filings/0001200375-25-000016.md) | [24.7% d](/filings/0001200375-26-000006.md) | [(57.1%)](/filings/0001200375-26-000012.md) | [(80.5%)](/filings/0001200375-26-000019.md) | | Diluted EPS | $ per share | [(0.29)](/filings/0001200375-25-000016.md) | not reported | [(0.25)](/filings/0001200375-26-000012.md) | [(0.16)](/filings/0001200375-26-000019.md) | [(0.22)](/filings/0001200375-25-000016.md) | not reported | [(0.10)](/filings/0001200375-26-000012.md) | [(0.13)](/filings/0001200375-26-000019.md) | | Free cash flow | $m | [(14.0) d](/filings/0001200375-25-000016.md) | [(18.2) d](/filings/0001200375-26-000006.md) | [(15.1)](/filings/0001200375-26-000012.md) | [(20.5) d](/filings/0001200375-26-000019.md) | [(7.9) d](/filings/0001200375-25-000016.md) | [19.6 d](/filings/0001200375-26-000006.md) | [(13.3)](/filings/0001200375-26-000012.md) | [(10.5) d](/filings/0001200375-26-000019.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [105](/filings/0001200375-24-000009.md) | [139](/filings/0001200375-25-000003.md) | [70.1](/filings/0001200375-26-000006.md) | [59.3](/filings/0001200375-26-000006.md) | [70.4](/filings/0001200375-26-000006.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(21.7%)](/filings/0001200375-24-000009.md) | [(25.2%)](/filings/0001200375-25-000003.md) | [(97.0%)](/filings/0001200375-26-000006.md) | [(98.6%)](/filings/0001200375-26-000006.md) | [(59.3%)](/filings/0001200375-26-000006.md) | | Net margin | % | [(20.3%)](/filings/0001200375-24-000009.md) | [(24.2%)](/filings/0001200375-25-000003.md) | [(108.7%)](/filings/0001200375-26-000006.md) | [(110.0%)](/filings/0001200375-26-000006.md) | [(62.5%)](/filings/0001200375-26-000006.md) | | Diluted EPS | $ per share | [(0.33)](/filings/0001200375-24-000009.md) | [(0.51)](/filings/0001200375-25-000003.md) | [(1.12)](/filings/0001200375-26-000006.md) | [(0.89)](/filings/0001200375-26-000006.md) | [(0.50)](/filings/0001200375-26-000006.md) | | Free cash flow | $m | [(28.1)](/filings/0001200375-24-000009.md) | [3.0](/filings/0001200375-25-000003.md) | [(57.1)](/filings/0001200375-26-000006.md) | [(53.7)](/filings/0001200375-26-000006.md) | [(23.8)](/filings/0001200375-26-000006.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cdxs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $16.5m | 7,284,352 | | Added +255,579 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $15.3m | 6,785,000 | | Unchanged | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $15.3m | 6,769,954 | | Reduced −1,910,414 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $12.5m | 5,549,139 | | Added +1,551,009 | | [Telemark Asset Management, LLC](/funds/1420816.md) | 2026-06-30 | $8.7m | 3,846,411 | | Unchanged | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $8.6m | 3,809,440 | | Added +408,944 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.2m | 3,623,613 | | Reduced −500,000 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.2m | 3,623,613 | | Reduced −500,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.2m | 3,617,109 | | Reduced −51,398 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.9m | 2,162,393 | | Added +277,040 | ## Recent filings [All 1,001 filings](/companies/cdxs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:21 ET | [10-Q](/filings/0001200375-26-000019.md) | Quarterly report, period 2026-06-30 | 0001200375-26-000019 | | 2026-08-11 | 16:11 ET | [8-K](/filings/0001193125-26-344646.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344646 | | 2026-07-27 | 16:02 ET | [8-K](/filings/0001193125-26-318042.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-318042 | | 2026-07-23 | 16:22 ET | [8-K](/filings/0001193125-26-314158.md) | 2.02 Results of operations; 8.01 Other events | 0001193125-26-314158 | | 2026-06-22 | 06:02 ET | [8-K](/filings/0001193125-26-276602.md) | 5.07 Shareholder vote results | 0001193125-26-276602 | | 2026-05-07 | 16:20 ET | [10-Q](/filings/0001200375-26-000012.md) | Quarterly report, period 2026-03-31 | 0001200375-26-000012 | | 2026-05-07 | 16:15 ET | [8-K](/filings/0001193125-26-211956.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211956 | | 2026-04-28 | 16:08 ET | [DEF 14A](/filings/0001193125-26-186994.md) | Proxy statement, period 2026-06-17 | 0001193125-26-186994 | | 2026-04-14 | 16:01 ET | [8-K](/filings/0001193125-26-154866.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-154866 | | 2026-03-11 | 16:39 ET | [10-K](/filings/0001200375-26-000006.md) | Annual report, period 2025-12-31 | 0001200375-26-000006 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001200375-26-000006.md), filed Mar 11, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/56e8172b-993d-4e24-a0c6-b9a928db7b76) ## About the filer - CIK: 1200375 - Tickers: CDXS - Exchange: Nasdaq - SIC code: 2860 Industrial Organic Chemicals - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:38 ET. No prices; not investment advice.